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ABSTRACT 
A Quality Improvement Project to Increase Hepatitis A and B Vaccination in Adults with 
Hepatitis C in a Federally Qualified Health Center 
 
                                                   Virginia M. Selanik 
 
 
Problem Statement Despite long-standing recommendations for vaccination against hepatitis A 
virus (HAV) and hepatitis B (HBV) in persons with chronic liver disease and hepatitis C virus 
(HCV) infection and the life-threatening complications suffered from cirrhosis and 
hepatocellular cancer (HCC), vaccination rates for HAV and HBV in adults are suboptimal in 
clinical practice. 
Theoretical FrameworkBased upon published clinical guidelines and performance measures for 
optimal care of HCV-infected persons, a quality improvement project was implemented guided 
by Kotter’s eight-step change model.  Strategies adopted from the 4 Pillars™ Practice 
Transformation Program, including staff/provider education, standing orders, immunization 
champions, open access/walk-in vaccination during office hours, posters promoting vaccination 
electronic medical record (EMR) reminders, patient post card reminders, and weekly charts to 
track progress were used.  
Project Description Retrospective EMR reviews from patients with a detectable HCV viral load 
(HCV RNA) were conducted at the start of the project and three months following the 
intervention. Demographic data along with HCV RNA, HAV total antibody (HAV Ab), HBV 
surface antibody (HBsAb), and vaccination against HAV and HBV were derived from EMR 
reports, comparing vaccination rates before and after the intervention. A secondary goal included 
increasing provider and staff knowledge related to hepatitis and clinical guideline 
recommendations for immunization against HAV and HBV in persons with chronic liver disease 
and HCV infection.  Using a quasi-experimental, one group pretest-posttest design, health care 
providers’ and staff members’ knowledge related to hepatitis and clinical guideline 
recommendations for immunization against HAV and HBV were evaluated before and after the 
educational intervention using 20-items from a pretest-posttest questionnaire. 
Findings and Implications The educational intervention significantly increased the providers’ 
and staff knowledge about hepatitis C. There was an average gain of 16.76 points (95% 
confidence interval, 13.32, 20.20) on a knowledge test after the educational presentation. This 
gain was statistically significant at p ≤ .05 by the paired t-test (two-tailed). Improvements were 
seen for Havrix (16.9% pre-intervention, 19.7% post-intervention); Engerix-B (2.3% pre-
intervention, 3.5% post-intervention); and Twinrix (20.8% pre-intervention, 21.4% post-
intervention). Overall vaccination rates were increased by 4.6% in a predominantly publicly 
insured patient population. The goal of increasing vaccination rates by 20% was not met.  
However, multi-strategy, evidence-based interventions were an effective means of increasing 
HAV and HBV vaccinations in a community health center and led to increased access to 
vaccination services, increased community demand for vaccines, and improved system-based 
performance. 
HEPATITIS VACCINATION IN ADULTS WITH HEPATITIS C                                          iii   
Dedication 
 
I dedicate this work to my patients, without whom this project would not have been possible and 
to my mother, Virginia E. Selanik, who taught me the value of lifelong learning, just because… 
you can and want to. 





 Thanks to each of you without whose help along the way – this journey would not have 
been possible. 
• To my committee members, Dr. Emily Barnes, Dr. Toni DiChiacchio, and Lisa Sullivan, 
APRN, FNP-BC -  My sincere thanks for your insight, guidance, and time during this 
project. I am especially grateful to Dr. Barnes for her mentorship and keeping me on task. 
You are truly an admirable young woman! 
• To Jennifer Krupp (Elyse) – for your invaluable statistical support and guidance in 
bringing the project to completion. 
• To my work colleagues – especially Susan for your ongoing support and feedback. 
• To my IT support – especially Tawnya and Carissa 
• To my computer geeks – Brenda and Scott, I could not have survived without your 
generous help at a moment’s notice. You rescued me so many times! 
• To my family- for your love and support and tolerating my messy apartment and 
obsessive worry over “getting my work done”. 
 
HEPATITIS VACCINATION IN ADULTS WITH HEPATITIS C  v. 
 
Table of Contents 
 
Abstract  
Dedication .................................................................................................................................... iii. 
Acknowledgements ...................................................................................................................... iv. 
Table of Contents ......................................................................................................................... v. 
Introduction ...................................................................................................................................  1 
Background .................................................................................................................................... 2 
Epidemiology of the Problem ............................................................................................ 2 
Hepatitis C ......................................................................................................................... 3 
Hepatitis B ......................................................................................................................... 4 
Hepatitis A ......................................................................................................................... 5 
Significance .........................................................................................................................6 
Description of the Population ............................................................................................ 6 
Setting ................................................................................................................................ 7 
Unique Factors Contributing to the Problem ..................................................................... 8 
Literature review and Synthesis ..................................................................................................... 9 
 Search Strategy .................................................................................................................. 9 
 Literature Review .............................................................................................................. 9 
 Synthesis .......................................................................................................................... 22 
Theoretical Framework ................................................................................................................ 24 
 Strategies From the 4 Pillars™ Practice Transformation Program.................................. 24 
 Kotter’s Eight Stages of Change Management ............................................................... 24 
Project Design ............................................................................................................................. 29 
 Guidelines and Benchmarks for CHC Care .................................................................... 30 
 Congruence of Organization’s Strategic Plan to Project ................................................ 31 
 Procedure ........................................................................................................................ 32 
 Timeline of Project Phases ............................................................................................. 34 
HEPATITIS VACCINATION IN ADULTS WITH HEPATITIS C   vi. 
 
 Resources, Personnel, Technology, and Budget ..............................................................35 
Measurable Project Outcomes ..........................................................................................37 
 Evaluation .........................................................................................................................37 
Results ...........................................................................................................................................38 
 Provider and Staff Demographics .....................................................................................38 
 Provider and Staff Knowledge ..........................................................................................39 
 Patient Demographics .......................................................................................................40 
 Vaccinations .....................................................................................................................42 
 Program Cost and Sustainability ......................................................................................44 
Discussion and Recommendations ...............................................................................................44 
Conclusion ....................................................................................................................................46 
Attainment of DNP Essentials ......................................................................................................46 
References ....................................................................................................................................48
HEPATITIS VACCINATION IN ADULTS WITH HEPATITIS C          vii. 
 
List of Tables and Figures 
 Table 1 – Provider and Staff Demographics ....................................................................39 
 Table 2 – Paired Samples Test .........................................................................................40 
 Table 3 – Pre-intervention and Post-Intervention Ages ...................................................41 
 Table 4 – Pre-intervention and Post-Intervention Gender ................................................41 
 Table 5 – Pre-intervention and Post-Intervention Payor ..................................................42 
 Table 6 – Pre-intervention and Post-Intervention Vaccinations .......................................43 
 Figure 1 – Project Model ..................................................................................................29 
 Figure 2 – Timeline of Project Phases ..............................................................................35 
HEPATITIS VACCINATION IN ADULTS WITH HEPATITIS C   viii. 
 
Appendix 
 Appendix A – Definition of Terms ..................................................................................56 
 Appendix B – Patient Reminder Postcard ........................................................................57 
 Appendix C – Authorization .............................................................................................58 
 Appendix D – Curriculum Outline .................................................................................. 61 
 Appendix E – Power Point Presentation for Provider and Staff Education .....................62 
 Appendix F – Education Poster for Staff Break Rooms ...................................................67 
 Appendix G – Pretest-Posttest for Providers and Staff.....................................................68 
 Appendix H – Poster for Exam Rooms.............................................................................76 
 Appendix I – Weekly Progress Charts..............................................................................77 
 Appendix J – Project Budget ...........................................................................................78 
 Appendix K – Letter of Support.......................................................................................79 
1 





A Quality Improvement Project to Increase Hepatitis A and B Vaccination in Adults with 
Hepatitis C in a Federally Qualified Health Center 
 
The global trends and adverse health impacts of hepatitis C (HCV) infection are among 
the major urgent public health challenges of our time. Superinfection with hepatitis A virus 
(HAV) or hepatitis B virus (HBV) in patients with chronic hepatitis C (CHC) infection is 
associated with the development of cirrhosis and hepatocellular carcinoma (HCC), which is the 
fastest rising cause of cancer-related death in the United States (Ward, Lok, Thomas, El-Serag, & 
Kim, 2012). HAV and HBV are both vaccine-preventable diseases and vaccines have been 
shown to be safe and effective in patients infected with HCV. Unfortunately, HCV vaccine 
development has been especially challenging due to the vast diversity among the genetic 
sequence of the seven different known genotypes of HCV, and there is no available vaccine for 
HCV (Ogholikhan & Schwarz, 2016). However, preventing viral hepatitis through immunization 
is the most effective way to prevent HCC due to chronic HBV and HCV infections (Wright, 
2007).  
 These deficiencies highlight the need for a systematic assessment in the quality of 
vaccination care related to patients with HCV. This project sought to determine the effectiveness 
of an evidence-based intervention to increase hepatitis A and B vaccination in adults with HCV in 
a Federally Qualified Health Center and increase providers’ and staff members’ knowledge of 
hepatitis immunizations. Guided by Kotter’s eight stages of change model (Kotter, 1995), it 
included using strategies from the 4 Pillars™ Practice Transformation Program (Nowalk, et al., 
2016), immunization champions, and staff/provider education. 




Statement of the Problem 
Superinfection with HAV or HBV in patients with HCV is associated with an 
accelerated,natural history of liver disease and a higher risk of morbidity and mortality compared 
to those without underlying liver disease (Keeffe, 2006; Felson, Fishbein, & Litwin, 2010; Thudi, 
Yadav, Sweeney & Behari, 2013). Optimal care of HCV-infected persons includes providing 
preventive health measures as outlined in published clinical guidelines and performance 
measures, including HAV and HBV vaccination. Despite long-standing recommendations for 
vaccination against HAV and HBV in persons with CHC and the poor outcomes associated with 
the complications of cirrhosis and HCC, vaccination rates for HAV and HBV in adults are 
suboptimal in clinical practice (Hachem, Kramer, Kanwals, and El-Serag, 2008; Tenner, Herzog, 
Chadhari, Bini, and Weishel, 2012).  Therefore the question is: Does  use of a multipronged 
approach ( staff/provider education, standing orders, immunization champions, open-access/walk-
in vaccination during office hours, posters promoting immunization, EMR reminders, patient post 
card reminders, and weekly charts to track progress)  for primary care providers and their staff in 
an FQHC increase hepatitis A and B immunization rates and  provider /staff knowledge related to 
hepatitis immunizations  for adults with hepatitis C? 
Epidemiology of the Problem 
According to the US Centers for Disease Control and Prevention (CDC), HBV and 
 HCV together kill more people than all other infectious diseases combined, including human 
immunodeficiency virus (HIV ) (Klevens, Hu, Jiles, & Holmberg, 2012; National Academy of 
Sciences, 2017). HBV and HCV cause between 500,000 and 700,000 deaths in the world each 
year from chronic infection-related cirrhosis and HCC (Lavanchy, 2012). The Institute of 
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Medicine (IOM) issued a report on hepatitis and liver cancer in January 2010 and found that lack 
of knowledge and awareness about chronic viral hepatitis on the part of health care providers 
impedes current efforts to prevent and control HBV and HCV (Ward, et al., 2012). As the pool of 
persons with chronic liver disease is increasing, and HBV and HCV infections continue to rise, it 
is certain that a greater number of individuals with chronic liver disease will be at risk for 
superinfection with acute and chronic hepatitis. The role of immunization is critical, and vaccines 
against HAV and HBV are safe, well tolerated, and highly effective (Waghray, Waghray, 
Khallafi, & Menon, 2016).  Because HAV and HBV vaccination is less effective in patients with 
advanced liver disease, it is recommended that patients undergo HAV and HBV vaccination early 
in the natural history of their chronic liver disease (Keefe, 2006). 
Hepatitis C 
HCV infection is a leading cause of chronic liver disease and the primary indication for 
liver transplantation in the United States (US) (Tenner, et al., 2012). Estimated to affect 130 to 
185 million of the world’s population, nearly 500,000 people die of HCV–related conditions each 
year (Denniston et al., 2014). HCV becomes chronic in approximately 75-85% of cases, with an 
estimated 3 million to 4 million of the non-institutionalized civilian population in the US having 
chronic infection (CDC, 2017). With inclusion of the homeless, veterans, the incarcerated, 
nursing home residents, hospitalized patients, and immigrants, the true prevalence of HCV in the 
US is approximately 2% or 5.2 million persons (Chak, Talal, Sherman, Schiff, & Saab, 2011). It 
is transmitted primarily through percutaneous exposure that can result from injection-drug use, 
needle stick injuries, and inadequate infection control in health care settings (CDC, 2017). Highly 
effective new treatments are rapidly being approved, and the number of individuals who progress 
to advanced liver disease and HCC may be lowered with these treatments. However, studies have 
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suggested that mortality associated with HCV infection from liver failure or HCC will increase 
over the next two decades (Ghany, Strader, Thomas, & Seeff, 2009). This is consistent with a 
recent study by Denniston et al. (2014) which suggested that decreases in HCV prevalence were 
probably a reflection of increasing mortality from HCV-related conditions. Unfortunately, since 
2010, after years of declining rates, the incidence of HCV infection has increased by 75% (Dan, 
Moses-Einstein, & Valdiserri, 2015). The abrupt increase is likely due to the opioid and heroin 
epidemic and injectable drug use that has swiftly increased the transmission of HCV infection 
(Tsui, Evans, Lum, Hahn & Page, 2014).). HCV, in addition to causing substantial morbidity and 
mortality, has damaging economic consequences. When evaluating the lifetime health care costs 
associated with HCV infection and end-stage treatments such as liver transplants,costs can reach 
high into hundreds of thousands of dollars (U.S. DHHS, 2011). The U.S. Department of Health 
&Human Services Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis (2011) 
reported, compared with other patients of similar age and sex, managed-care enrollees with HCV 
infection are hospitalized more frequently and have higher annual health-care expenses ($21,000) 
exceeding the per-person costs associated with diabetes ($10,000). 
Hepatitis B 
 HBV remains a public health challenge with the CDC estimating approximately 850,000 
persons living with HBV in the US, and an estimated 21,900 new cases of HBV in 2015 
(CDC,2016). The number of reported cases of acute HBV increased by 20.7% to 3,370 cases in 
2015. It is transmitted by percutaneous or mucosal exposure to blood or body fluids of an infected 
person, such as from an infected mother to her newborn during childbirth, through close personal 
contact within households, through unsafe injections in health caresettings, through injection drug 
use, and from sexual contact with an infected person (CDC, 2016). HBV vaccine can provide 
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protection against infection and associated chronic complications. HBV vaccine is the first 
vaccine against a cancer, such as HCC, the first vaccine protecting persons from a sexually 
transmitted disease, and the first vaccine to ever be licensed against a chronic disease (Lavanchy, 
2012). The annual medical care costs of HBV infection have been estimated to be as high as 1.1 
billion dollars (Ward et al., 2012). 
 
Hepatitis A 
Hepatitis A infection accounts for up to half of the reported cases of acute viral hepatitis in 
the US (Reiss & Keeffe, 2004), with the estimated number of new HAV infections in 2015 
reported to be 2,800 (CDC, 2016). It is transmitted through the fecal oral route and acquired in the 
US primarily through close contact with an infected person and during foodborne outbreaks. 
Infection with HAV confers life-long immunity and does not cause chronic infection. Although 
HAV infection is a self-limiting illness, a small subset of persons will progress to fulminant 
hepatic failure and death or transplantation (Reiss &Keeffe, 2004). According to recent studies, 
the incidence of HAV has declined primarily due to implementation of immunization policies and 
improvement in environmental hygiene (Samandari, Bell, & Armstrong, 2004; Wasley, 
Samandari, & Bell, 2005). However, there is an emergence of a new cohort of persons who lack 
immunity to HAV and are at risk for HAV infection (Keeffe, 2006), with injection drug use as the 
predominant risk factor for this group (Quaglio, Lugoboni, Mezzelani, Des Jarlais, & Lechi, 
2006). HAV vaccination has been available since 1995 and has been shown to be safe and 
effective, with few adverse events (Reiss & Keeffe, 2004), but it wasn’t until 2006 that the 
Advisory Committee on Immunization Practices of the Centers of Disease Control and Prevention 
(ACIP) expanded immunization recommendations to include the routine vaccination of children 
aged ≥ 1 year in all 50 states (Dan, Eisenstein, & Valdiseri, 2015).  




In West Virginia, the incidence of acute HBV and acute HCV has increased 213% and 
209%, respectively as noted in the WV HBV and HCV Disease Surveillance Report 2012-2015. 
The WV-State Health Profile reported cases of acute HAV did not increase between 2011 and 2015, 
rates of acute HBV increased by 146%, and cases of HCV increased by 36% (CDC, 2015). In 
comparison to national rates, West Virginia reported the highest incidence of acute HBV infection 
at 14.7 per 100,000 population and the second highest rate of HCV infection at 3.4 per 100,000 
population in the US in 2015, which is five times the national average (CDC, 2015). Injection drug 
use is the most common risk factor for HCV infection in the US and is the key driving force in 
perpetuating the epidemic of HCV infection and opioid-related deaths (Tsui et al., Evans, Lum, 
Hahn, & Page, 2014). A rise in new HCV infections has been noted among white adolescents and 
young adults with a history of injection drug use and prescription opioid use (Hagan & Schinazi, 
2013). The Centers for Disease Control and Prevention estimates that nearly 20,000 deaths were 
associated with HCV in 2014, making it one of the deadliest diseases in the US (CDC,2016). 
Description of the Population 
FamilyCare Health Centers serves over 30,000 people in four counties in south-central 
West Virginia, a state that lies entirely within the Appalachian region. The region is burdened 
with high rates of chronic illnesses (e.g., diabetes, heart disease, cancer, HCV) and poor health 
habits (e.g., sedentary lifestyle, tobacco use, prescription drug abuse). The target population is 
those people living in FamilyCare’s Service Area with incomes under 200% of the Federal 
Poverty Guidelines in Putnam, Boone, and certain census tracts in Kanawha and Mason counties. 
FamilyCare’s Service Area includes small towns and rural areas in addition to the cities of 
Charleston and Madison, West Virginia. 




The study took place in a Federally Qualified Health Center (FQHC) in West Virginia 
where primary care services for over 500 people with substance related disorders other than 
tobacco or alcohol were provided in 2016. The organization was a recipient of a Substance Abuse 
Service Expansion award in 2016. Through that funding, the organization was able to expand its 
integrated primary care/behavioral health model to add substance abuse services at four clinic 
sites. The increased number of patients with health-center funded Medical Assisted Treatment 
(MAT) made evident the alarming trend of increased numbers of patients with chronic HCV 
infection within the organization. At the project site in 2016, an estimated 310 (62%) of those 
patients with substance use disorders had a diagnosis of HCV. This is consistent with current 
published studies that have found certain vulnerable populations are disproportionately affected, 
such as in inner-city ambulatory primary care and Veteran’s Administration populations, where 
the rate of HCV infection is as high as 8%, and up to 80% among intravenous drug users 
( Alfandre, Gardenier, Federman, & McGinn, 2009).The need to develop and implement a change 
in service delivery at the clinical site based on the increasing  HCV patient population made a 
compelling case for implementing an innovative multi-strategy, evidence-based intervention to 
increase HAV and HBV vaccination efforts within the organization. 
Unique Factors Contributing to the Problem 
Left untreated, HCV can cause the liver to develop fibrosis, a structural change in the liver 
as a result of chronic injury with resultant increase in liver stiffness (Rockey, 2006). Increased 
stiffness in the liver occurs as liver fibrosis progresses causing resistance to liver blood flow. 
Lack of blood flow to the liver will eventually result in liver failure which results in cirrhosis over 
time. Progression of liver fibrosis is a sign of worsening chronic HCV infection which can lead to 
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cirrhosis and complications of end-stage liver disease including liver failure, ascites, bleeding 
from varices, hepatic encephalopathy, and HCC. The METAVIR  system is commonly used for 
grading activity and staging fibrosis (Bedossa & Poynard,1996).Serum markers used to predict 
fibrosis in hepatitis C patients are compared to biopsy results obtainedwith the five point scale 
METAVIR system, where fibrosis is described as follows: chronic hepatitis without fibrosis (F0); 
portal fibrosis without septae (F1); portal fibrosis with a few septae (F2); septal fibrosis without 
cirrhosis (F3) and complete cirrhosis (F4) (Rossi, Adams, Bulsara, & Jeffrey, 2007). The current 
West Virginia Medicaid Office of Pharmacy Services Prior Authorization Criteria for Chronic 
Hepatitis C Treatment (WV DHHS, 2017) restricts access to HCV treatment requiring that 
beneficiaries have a fibrosis scoreof F2 before they can access curative medical treatments. Up to 
20% of chronic HCV patients are cirrhotic when first presenting into care, and between 20% and 
30% of patients without cirrhosis will develop cirrhosis within one or more decades (Benvegnu, 
Gios, Buccato, & Alberti, 2004). Due to the high cost associated with medication regimens for 
treating HCV infection, many patients have been forced to delay treatment if liver histology 
displays minimal to moderate fibrosis.The need for protecting the health of the liver in patients 
with CHC is paramount in an era where criteria for treatment requires an F2 fibrosis score. Fewer 
than 11% of persons referred to care are treated (Dan et al., 2015), and there are many patients in 
West Virginia that are not getting treated, despite having infection and likelihood of disease 
progression.  Many patients are young injection drug users, who have F0 fibrosis scores, and do 
not meet the criteria for accessing the medication for treatment. As liver disease progresses, many 
immunizations lose their effectiveness (Leise & Talwalkar, 2012).   It is therefore important to 
address immunization needs in patients with CHC early on when immunizations are most 
effective. A greater risk of infection, coupled with a likely worse outcome, warrants vaccinating 
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these CHC patients against HAV and HBV, preferably as early as possible in the natural course of 
their illness (Reiss & Keeffee, 2004). 
Literature Review and Synthesis 
Search Strategy 
To identify the best evidence regarding increasing HAV and HBV vaccination rates in 
adults with hepatitis C, an in-depth search of the literature was performed. Inclusion criteria for 
the search were studies that addressed hepatitis, hepatitis C, vaccination, immunizations, quality 
improvement, or provider adherence. Databases searched included Academic Search Complete,  
Medline, CINAHL, and the Cochrane Library. Keywords used in the search were combinations of 
hepatitis, hepatitis C, vaccination, immunization, provider adherence, and quality improvement. 
The initial search of all databases yielded 22,939 hits. The search was narrowed to 368 articles by 
limiting it to articles from 2005-2017, English language, systematic reviews, clinical practice 
guidelines, randomized controlled trials, cohort studies, and peer-reviewed journals. The evidence 
base was narrowed further by excluding articles that did not contain the search terms of 
vaccination, immunization, or did not include information related to quality improvement. 
Snowballing technique was used to identify additional articles that met initial inclusion criteria. 
Twenty final articles were identified for review.  
Literature Review 
The 4 Pillars™ Practice Transformation Program model was used in 4 studies to test its 
effectiveness in increasing adult immunization rates in primary care. In a triangulated mixed 
methods study done by Nowalk et al. (2014), a standing order program toolkit from the 4 
Pillars™ Program was pilot-tested, evaluating changes in influenza and pneumococcal 
vaccination rates. Qualitative evaluation using on-site observation and interviews of practice staff 
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were used along with vaccination rates derived from the EMR between June 2011 and through the 
end of June 2012 in 4 primary care practices. Although response to the 4 Pillars™ standing orders 
toolkit may have differed in sites whose rates were initially higher, influenza rates increased 
significantly in 3 of the 4 sites. In a randomized controlled cluster trial, Nowalk et al. (2016) used 
the 4 Pillars™ Practice Transformation Program as the foundation of a 2- year study to increase 
adult immunization rates for influenza, pneumococcal and Tdap among patients of primary care 
practices in two cities. The purpose of the study was to report on changes in adult Tdap 
immunization rates and factors related to the likelihood of receipt of this vaccine. In the first year, 
cumulative Tdap vaccination increased significantly in both intervention and control groups.  The 
percentage point increases in the intervention groups (7.7 PP in Pittsburgh and 9.9 PP in Houston) 
were significantly higher (P< 0.001) than in the control groups (6.4 PP in Pittsburgh and 7.6 PP in 
Houston). In the Year 2 pre-post study, in both cities, active intervention groups increased rates 
significantly more (6.2 PP for both) than maintenance groups (2.2 PP in Pittsburgh and 4.1 PP in 
Houston; P<0.001). The study reported both clinically and statistically significant improvements 
in Tdap vaccination rates in diverse primary care practices using the 4 Pillars™ Practice 
Transformation Program and these changes were maintained in the post-intervention period. 
Zimmerman et al. (2017) completed a 20-month randomized controlled cluster trial in 25 primary 
care practices stratified according to metropolitan area (Houston, Pittsburgh), location (rural, 
urban, suburban), and type (family medicine, internal medicine). The aim was to test the 
effectiveness of the 4 Pillars™ Practice Transformation Program, to increase pneumococcal 
vaccination in individuals aged 65 and older. Using the 4 Pillars™ program and one-on-one 
coaching of practice-based immunization champions, pneumococcal vaccination rates increased 
significantly in all intervention and control groups, with average increases ranging from 6.5 to 8.7 
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PP (P<.001). The likelihood of pneumococcal vaccination in the Year 2 pre-post study was 
significantly higher in the active intervention sites than the maintenance sites in Pittsburgh, but 
not in Houston. The strengths of this study included its randomized design, large diverse sample 
size, diverse practice settings, and two intervention years of vaccination reporting. Weaknesses: 
delivery of EMR data was delayed in Year 1 intervention, which prevented the researchers from 
providing feedback about their progress to the sites in both cities. In another randomized 
controlled cluster trial by Zimmerman et al. (2017) that took place during 2013-2015, strategies 
from the 4 Pillars™ Practice Transformation Program were used to increase HPV vaccination 
uptake in primary care sites among 10,862 adolescents in 9 intervention and 11 control sites. The 
strategies included improving patient notification about needed vaccines, increasing convenience 
of vaccines, implementing standing order protocols, creating an immunization champion role, 
supporting the use of site-specific immunization strategies via conference calls, an on-line 
dashboard to track progress, and motivating staff by sharing progress towards goals via progress 
charts. The interventionsites increased HPV initiation 10.2 PP compared with 7.3 PP in control 
sites (P<0.001). Completion rates for the HPV series did not differ between groups. Strengths of 
this study was the randomized design and the large sample size. The modest length of the 
intervention limited its ability to observe differences in HPV series completion between the 
groups.  
Campbell et al., (2006) completed a 32- month randomized controlled trial with a sample 
of 3,181 young urban injection drug users in five US cities to assess whether convenience and 
monetary incentives influenced uptake of vaccinations. The purpose of the study was to describe 
antibody to HAV (anti-HAV) and total antibody to hepatitis B core antigen (anti-HBc) 
seroprevalence self-reported prior vaccination, and acceptance of free HAV and HBV vaccine by 
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18-30 year old injection drug users. It also assessed structural and individual factors associated 
with vaccine uptake. Anti-HAV and anti-HBc seroprevalence was 19% and 23%, respectively. 
Lack of awareness was the most common reason for no previous HAV or HBV vaccination. Only 
36% received > than 1 dose, even though 83% of participants were willing to be 
vaccinated.Participation was highest when vaccine was immediately available and lowest when 
offered only after receiving results. Strength of the study: uniform procedures used for counseling 
and testing across 5 study sites. Weaknesses were that the study only recruited young urban IDUs, 
and the sample may not be representative of older IDU populations. This study was unable to 
determine the validity of self-reported HAV and HBV vaccination history. Considering anti-HAV 
and anti-HBs wane with time, serologic testing results might not have correlated with true 
vaccination history and true immunity. 
 Felson et al. (2010) conducted a retrospective review of a random sample of 207 medical 
records of patients enrolled in an academically affiliated, urban methadone maintenance program 
providing on-site primary care services. The aims of the study were to examine the rates of testing 
for HAV, HBV, and HCV, as well as rates of vaccination against HAV and HBV in patients with 
CHC infection in the program. The study found almost all patients reviewed were tested for HAV, 
HBV, and HCV. There were 111 patients chronically infected with HCV. Of those patients, 53 
(48.6%) and 68 (63%) were found to lack immunity to HAV and HBV respectively. Of those 
lacking immunity, 29 (54.7%) and 2 (2.9%) were then vaccinated for HAV and HBV 
respectively. It was not clear why rates of vaccination were low in comparison to the high rates of  
clinic visits.  These visits may represent missed opportunities for vaccination. Strengths of this 
study included the high rates of screening for HAV, HBV, and HCV. Because of the retrospective 
chart review, some data may have been missed if a patient was vaccinated outside of the clinic, 
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causing the researchers to underestimate the proportion of eligible patients who were ultimately 
vaccinated.  
 In a prospective cohort study of 68 participants from 20 primary care practices, each with 
a team of 4 members, Gannon et al. (2012) studied the effect of using a team approach on 
improving adult immunization practices in the primary care setting. Each practice designed their 
own practice team. Participants were given access to an on-line educational program after a 
baseline physician practice pattern survey and 35 random patient chart abstractions were 
completed. Data also revealed an increase in the number of physicians who discussed herpes 
zoster and pneumococcal immunizations with their patients (23.2% pre-intervention, 43.4% post-
intervention; P≤.01) as well as an increase in physicians using the CDC immunization schedule 
(52.9% pre-intervention, 88.2% post-intervention; P≤.02). Knowledge scores did not differ 
significantly between before and after intervention showing that knowledge is necessary, but not 
sufficient to increase immunization rates. The information bias of physician self-report via the 
survey data was a limitation of this study as they might have under-reported or over-reported 
behavior.  
 Hachem et al. (2008) conducted a retrospective cohort study of 243 HCV-infected patients 
after calculating predictive values for hepatitis vaccination codes in a validation set of 168 
patients. The purpose of the study was to validate Current Terminology (CPT) codes and drug 
codes for hepatitis vaccination in administrative databases and determine vaccination rates in 
HCV-infected patients in a single large veterans Administration Medical Center. Among patients 
diagnosed with HCV between 2000 and 2005, receipt of hepatitis vaccination was documented in 
approximately 8% overall. Of the 3,009 patients diagnosed with HCV during 2000-2005, 7.9% 
had a HAV vaccination and 8.6% had a HBV vaccination. Of the 57 HCV-infected patients who 
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received HAV vaccination, 100% had HAV serology testing and the majority (89%) had negative 
HAV serology. Approximately 70% of patients who received a HAV vaccination did receive a 
full series. Pre-vaccination serology indicated positive immune status prior to HAV vaccination in 
two (3.5%) of these patients. All 49 patients who received HBV vaccination had testing for HBV 
serology. Six of these patients (12%) had positive serology prior to receiving HBV vaccination. In 
patients who did not receive hepatitis vaccinations, chart review indicated that 66-96% had HAV 
or HBV serology checked and approximately one-third had negative HAV or HBV serology 
indicating susceptibility to co-infection and potential missed opportunities for vaccination. The 
initiatives coincided with an observed increase in vaccinations and demonstrated the potential for 
facility determinants in improving outcomes of care to this high-risk population. These findings 
have limited generalizability to the VA system as they were derived from a single VA center and 
may not reflect the coding practices of other VA sites.  
A retrospective cohort study conducted by Hechter et al. (2014) examined HBV testing 
and vaccination practices in adults infected with chlamydia, gonorrhea, or syphilis seeking care in 
non-STD clinics of a large managed care organization in 2008-2011. The study revealed  
that < 30% of subjects were screened for active HBV infection (HBsAg) within 90 days following 
a STI diagnosis, although the testing rate did increase slightly each year, from 24.7% in 2008 to 
30.3% in 2011. Only 8.8% of the subjects received both HBsAg and HBsAb testing for evaluation 
for vaccination need. Among those who were susceptible to HBV infection, only about 11% 
initiated the HBV vaccine series. This finding suggests that healthcare providers do not frequently 
identify candidates for HBV vaccination as part of routine clinical services, even though HBV 
vaccination is recommended for persons seeking STI evaluation or care. Avoiding the problem of 
potential selection bias and high attrition through the efficient use of an EMR database to identify 
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a large cohort of adults who were diagnosed with STIs and followed up on their HBV testing and 
vaccination status was a strength of the study. One limitation was the inability to ascertain 
complete history of HBV vaccination and chronic HBV infection that occurred before a person’s 
enrollment in the managed care organization.  
 Hernandez et al. (2009) conducted a retrospective cohort study that included 2,968 CHC 
patients examining HAV and HBV serology data and immunization records between 2000 and 
2007 using a hospital EMR system.  All patients were veterans receiving care from a multi-
campus tertiary referral teaching hospital affiliated with Stanford University. The primary  
purpose of the study was to determine the percent of patients with CHC who met the recently 
adopted performance measure on vaccination against both HAV and HBV and were either tested 
for antibody to HAV and HBV and subsequently immunized with HAV and/or HBV vaccine, if 
they received the vaccine without antibody testing. Secondary objectives were todetermine the 
immunity to HAV and HBV, adherence rate with completing the vaccination series, and the 
reasons for non-adherence to the recommendation. The researchers found overall adherence to the 
performance measure to vaccinate all HCV-positive patients for both HAV and HBV was 62%. 
There were 1,834 patients found to either have documented immunity to or have received 
vaccination for both HAV and HBV. Only 261 (9%) were adherent to the HAV performance 
measure and 231 (8%) adherent to the HBV performance measure. Of the 964 patients vaccinated 
for HAV, only 684 (71%) completed vaccination series. There were 1,283 patients vaccinated for 
HBV and 654 (51%) completed the series. There were 231 patients who did not have documented 
immunity or receive vaccination for HAV, 261 patients with no documented immunity to HBV, 
and 641 patients who had no documented immunity to both HAV and HBV. Reasons for non-
adherence included:  missed opportunity (41%), patient did not return after diagnosis of HCV 
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(31%), documentation of vaccination outside of clinic (22%), and newly diagnosed within 3 
months from the end of the study period, with no clinic visit since the diagnosis (4%).Strengths of 
the study included the large sample size with long-term follow up, and accurate data capture with 
EMR. The retrospective design was a limitation of the study and those vaccinated outside of the 
clinic were not counted as vaccinated.  
 Kanwal et al. (2010) completed a retrospective cohort study to evaluate the quality of 
health care that patients with HCV receive and the factors associated with receipt of quality care 
in response to the quality-of-care indicators proposed by Medicare for HCV infection. The study 
cohort of 10,385 patients was drawn from the research database of a large commercial health 
insurance carrier enrolled in the database between 2003 and 2006. Quality of care was measured 
by 7 explicit quality indicators included in Medicare’s 2009 Physician Quality Reporting 
Initiative. Performance for vaccination was lowest with few (21%) receiving HAV vaccination 
and 26% receiving HBV vaccination. Most of the indicators were relatively insensitive to coding 
errors due to billing requirements and there were 99% of HCV viral load test results derived from 
the laboratory results file that had matching claims in the claims file. The retrospective 
observational design using a convenience sample was a limitation to the study. 
 A follow up study by Koenig et al. (2016) assessed recent changes in HAV and HBV 
vaccination rates with chronic liver disease and type II diabetes in the US using population data 
from NHANES cycles 2009-2012 and 2012-2013 and compared those to previous cycles from 
1999-2004 and 2005-2008. There were 29,404 participants. The researchers measured serologic 
immunity or history of vaccination. In the US population, the rates of quality measure (QM 
serologic immunity or history of vaccination) for HBV increased from 31.9% in 1999-2004 to 
49.5% in 2013-2014 (P<0.001). A similar increase was noted for HAV: 12.0% in 1999-2004 to 
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33.4% in 2013-2014 in vaccination, 44.0% to 52.4% in HAV QM (all P<0.0001). Greater  
increases were found in non-HBV chronic liver disease patients: 34.7% to 56.8% in HBV QM 
and 22.7% to 51.1% in HBV vaccination ( all P<0.0001). In this study, both HAV and HBV 
vaccination rates in the US and in subpopulations with chronic liver disease were steadily 
increasing. However, the majority of the US population remained susceptible to HAV and HBV 
throughout the study years, and it was only in the most recent years from 2013-2014 that both 
quality measures approached the 50% value. The researchers suggested that linking people with 
diabetes and chronic liver disease to accessible, affordable preventive care may be necessary to 
improve vaccination rates for HAV and HBV in these vulnerable groups. Weaknesses of the study 
included self-reported vaccination history which may have recall bias and the NHANES sample 
may be biased as it did not include incarcerated, institutionalized, or homeless persons.  
 Kramer et al. (2011) used a retrospective cohort design to determine the proportions of 
patients who met the Medicare quality measure for vaccination for HAV and HBV in a national 
cohort of 88,456 HCV-infected patients who received care in VA facilities. The overall 
vaccination rates of 20.7% for HAV and 21.9% for HBV were low. The quality measure rates 
were 57.0% and 45.5% for HBV and HAV, respectively. Factors related to HCV care were also 
determinants of meeting the HBV quality measure. These factors included receiving a specialist 
consult, genotype testing, or HCV treatment. Patients who were older, had psychosis, and had a 
higher comorbidity score were less likely to meet the HBV quality measure. Similar variables 
were related to meeting the HAV quality measure with few exceptions. Incidence of 
superinfection with acute HAV and HBV was significantly lower in patients who received 
vaccination than in those who did not. Validity concerns were alleviated by the fact that 
laboratory values and ICD-10 codes from the clinical case registry were highly accurate . 
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A retrospective review was conducted by Loy, Kwiatt, Dodda, Martin, Dua, & Saeian 
(2016) to identify adherence to quality measures for cirrhosis which included HAV and HBV 
immunization. Prospectively, they measured compliance with quality measures at 1-month, 2-
month, 1-year, and 3-year follow-up after performance feedback. Baseline HAV and HBV 
immunization was 51% and 47%, respectively. After performance feedback, HAV and HBV 
vaccination rates improved to rates ranging from 92% to 100% and remained statistically 
significant (P<.0001) over a 3-year time period. Weaknesses of this study included reliance on 
chart review and that the performance feedback was provided to a group of health care providers 
as opposed to individual providers.  
 In a retrospective pre-post study, Petroll et al. (2014) compared rates of preventive health 
delivery to HIV patients at an outpatient clinic during the use of paper medical records (PMR) 
and implementation of an EMR. The study sought to determine the impact that an EMR had on 
the provision of preventive health measures that included obtaining serologies for viral hepatitis 
and administering vaccinations to non-immune HIV patients. The sample consisted of 160 active 
patients whose charts were randomly selected for review at two time points: 12-16 months prior 
to and 24 months following EMR implementation. There was no difference between the PMR and 
the EMR with regard to proportion of patients who had HAV (83% in PMR group and 77% in 
EMR group) and HCV (94% in both groups) serologies measured or the proportion of eligible 
patients who were given hepatitis vaccinations. Slightly fewer had serology for HBV measured. 
EMR had no effect on vaccination administration.  A strength of the study was the random 
selection of charts. The pre-post comparison was a weakness as some of the patients could have 
received vaccinations that were not documented prior to the study. 
HEPATITIS VACCINATION IN ADULTS WITH HEPATITIS C 19 
 
 
 Ramirez et al. (2016) conducted a before and after cohort study to review HAV and HBV 
antibody testing and vaccination status of patients with chronic liver disease in a liver clinic. They 
attempted to improve vaccination rates by using a pre-printed order set with reminder check 
boxes to order serum antibody testing and HAV and HBV vaccinations for patients with chronic 
liver disease who had negative results. Patient records from a 2005 cohort before the intervention 
were compared with patient records from a 2008 cohort after the intervention. Among the chronic 
liver disease patients, those with HCV infection were the most likely to be screened for immunity 
to HAV and HBV. The raw number of patients screened increased from 157 to 440 for HAV and 
156 to 447 for HBV as well as the percentage of those who completed vaccinations. However, the 
percentage of completed vaccination was less in HBV immunization compared with HAV, most 
likely due to the multiple visits required to complete the HBV series (3 for HBV and 2 for HAV). 
A weakness of this study was that some patients in the 2008 cohort were likely the same patients 
from the cohort, so there was potential for overlap. Also, patients were classified by diagnosis 
with no account for severity of disease, which might have cause a pre-selection bias.  
Rowe, Parker, Armstrong, Houlihan, and Mutimer (2012) completed a meta-analysis of 10 
studies that included a total of 22,371 persons with HCV infection. The aim of the study was to 
determine the mortality risk of HAV superinfection in CHC infection, and to define the utility of 
HAV vaccination using incidence and mortality data. The studies reported the outcomes of cohort 
studies, population surveillance studies, and the outcomes of HAV outbreaks. The researchers 
estimated that 814,849 patients need to be vaccinated (at a cost of $80.1 million) to prevent one 
death per year from HAV in HCV- infected persons. Using the pooled estimate of increased 
mortality risk of HAV superinfection, the researchers estimated that two to three deaths per year 
are attributable to HAV superinfection in HCV-infected persons, or one in every 2,190 deaths 
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(0.05%) attributable to HCV infection. The study concluded that vaccination is unlikely to lead to 
a significant improvement in mortality in this population and that persons with HCV infection are 
at low risk from mortality due to HAV superinfection in low incidence areas such as the US.  In 
this meta-analysis of observational studies, significant heterogeneity between studies may have 
publication bias as CHC measured by polymerase chain reaction was only reported in one study. 
A strength of the study was the sensitivity to changes in incidence of HAV in analyzing cost-
effectiveness.  
 In a large retrospective cohort study of 1,193 patients diagnosed with CHC infection 
conducted at a New York Veterans Affairs healthcare system, Shim et al. (2005) found that 
despite multiple visits to their primary care physicians or to the Gastroenterology Clinic, only 
54% of the patients in the study who had CHC had been tested for HAV. Slightly more than half 
of those who were tested were susceptible to HAV but only 27% received at least one dose of the 
HAV vaccine. There were 323 patients (0.9%) who were already immune to HAV, and 1.1% of 
the 553 subjects who were never tested. Among the 94 vaccinated patients, 45 received only one 
dose of the vaccine. Three of the unvaccinated patients developed acute HAV infection during 
follow up and 1 of them died of acute liver failure. The large sample size, the availability of long- 
term follow up data, and the use of the computerized record system and pharmacy database to 
obtain detailed demographic and clinical data were strengths of the study. The retrospective 
design, the single center health system, and most patients being male were weaknesses of the 
study as findings may not be generalizable to other VA medical centers, non-VA settings, or 
women. Reasons for low HAV testing and vaccination rates in the patients could not be 
determined.  
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 A 2-page questionnaire was mailed to 3,000 primary care and internal medicine physicians 
randomly selected from the AMA Physician Masterfile in 2006 for a study conducted by Tenner 
et al., (2012). The purpose of the study was to determine primary care physician knowledge, 
attitudes, and barriers to vaccination against HAV and HBV in patients with chronic liver disease 
due to HCV, and to evaluate whether these differ between family medicine and internal medicine 
physicians. Completed surveys were returned by 1,209 (42.2%) of 2,862 eligible physicians There 
were 557 family medicine physicians and 652 internal medicine physicians in the sample. Family 
physicians were less likely to see more +HCV patients per week than internal medicine 
physicians (29.3% vs. 34.8%, p< 0.04). Fewer family medicine physicians compared with internal 
medicine physicians knew that HCV-infected patients who were HCV PCR positive should 
receive the HAV vaccine ((62.7% vs. 76.5%, p<0.006) and the HBV vaccine (65.4% vs. 79.6%, 
p<0.001). Compared with internal medicine physicians, a consistent, significantly lower 
percentage of family medicine physicians felt that the HAV and HBV vaccines were safe and 
effective and that HCV patients should be vaccinated for HAV and HBV. A low proportion of 
both groups of physicians reported that HAV/HBV testing should be done prior to vaccinating. 
The survey was pre-tested prior to mailing by both gastroenterologists and primary care 
physicians for clarity and consistency. The relatively large, randomly selected sample of 
physicians from a comprehensive physician database was anonymous and geographically diverse, 
which were strengths of the study. A weakness of the study was due to the self-reported nature of 
the survey, which may not have reflected actual practice patterns of the respondents. 
 During a 12-month retrospective cohort study in 2008 conducted at the Center for Liver 
Diseases of the UPMC-Presbyterian Hospital, Thudi et al. (2013) reviewed the records of 705 
patients who had chronic liver disease meeting criteria for vaccination for HAV and HBV and had 
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a minimum of 2 follow-up visits during the study period. The objectives of the study were to 
evaluate adherence to hepatitis vaccination guidelines in patients with chronic liver disease at a 
tertiary hepatology clinic, to identify barriers to vaccinations in patients with chronic liver 
disease, and to determine physician variability in adherence to vaccination guidelines. HAV 
antibody was tested in 619/705 patients (87.7%) and of those, 29.5% tested positive for HAV 
antibody (immunity). There were 637/705 patients tested for HBsAg (90.4%), 596/705 (84.5%) 
tested for HBsAb, and 591/705 (83.8%) tested for HBcAb. Of those patients, 29.5% tested 
positive for HBsAb (immunity due to previous vaccination or past infection). Vaccination for 
HAV was recommended to 63% of the patients and 177 (68.3%) underwent vaccination.  HBV  
vaccination was recommended to 59.7% of the patients. Significant variability was observed in 
vaccination recommendation amongst individual providers (30-98.6%). There were no differences 
in vaccination rates for Medicare patients with HCV infection for whom a vaccination reminder 
was automatically generated by the EMR. Insurance was a barrier in a minority of patients. This 
study showed that vaccination rates for hepatitis were low even in an academic, sub-specialty 
clinic. This retrospective study was performed at a single center and did not record differences 
between physicians and advanced practice providers that might have explained the individual 
variability in vaccination recommendation rates. Also, the EMR-based reminders were only 
required during the study period for Medicare patients with HCV, so results on the automated 
computerized reminders may not be generalizable to other groups of patients.  
 
Synthesis 
 The evidence collected through the evaluation of 20 documents including four randomized 
controlled studies (Campbell et al., 2007; Nowalk et al., 2016; Zimmerman, et al., 2016; and 
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Zimmerman et al., 2017), one meta-analysis (Rowe, Parker, Armstrong, Houlihan, and Mutimer, 
2012); 11 retrospective cohort studies ( Felson et al.,2010; Hachem et al., 2008; Hechter et al., 
2014; Hernandez et al., 2009; Kanwal et al., 2010; Kramer et al., 2011; Loy et al., 2016; Petroll et 
al., 2014; Ramirez et al., 2016; Shim et al., 2005;Thudi et al., 2013), one mixed methods study 
(Nowalk et al., 2014), one follow up study (Koenig et al., 2016), one prospective cohort study 
(Gannon et al., 2012) and one survey (Tenner et al., 2012) support the need for multi-strategy 
interventions to increase hepatitis A and B vaccination rates in HCV-infected persons. Only one 
study, the meta-analysis by Rowe et al., 2012, challenged the use of routine HAV vaccination in 
HCV-infected persons, and found the number needed to vaccinate to prevent one death per year 
would be costly at $80.1 million, which the researchers believed would likely expose many 
individuals to an intervention of no direct benefit. Thirteen of the 20 studies used retrospective 
EMR reports to gather data, which is an efficient way to identify a cohort of study subjects and 
avoids the problem of potential selection bias. However, although an EMR allows detailed and 
accurate data capture, the data were dependent on documentation that a vaccination was given and 
some of the patients that were vaccinated outside of the study sites were not counted as 
vaccinated. The research suggests that interventions aimed at systems rather than the patient have 
better success. Four of the studies used the 4 Pillars ™ Program and practices that used more 
strategies from the program demonstrated larger increases in adult immunizations. Based on the 
review of the literature, these studies support the finding that vaccination rates for HAV and HBV 
in adults with HCV are low and that delays in or lack of vaccination increases the morbidity and 
mortality of these patients.   
Theoretical Framework 
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A combination of evidence-based HCV recommendations, along with strategies adopted 
from the 4 Pillars™ Practice Transformation Program and Kotter’s eight step change model 
facilitated the design for this high-priority HCV practice change.  
Strategies From the 4 Pillars™ Practice Transformation Program 
Focusing on barriers and facilitators of adult immunizations from the provider and patient 
perspectives, the 4 Pillars™ Practice Transformation Program model provided a good fit for this 
project as it is an evidence-based compilation of best practices and step-by step guide for 
increasing adult immunizations in primary care settings, (Nowalk, et al., 2016). Developed by a 
team in the Department of Family Medicine, University of Pittsburgh School of Medicine, it is 
founded on four key domains: Pillar 1- Convenient vaccination services; pillar 2- Communication 
with patients about the importance of immunization and the availability of vaccines; Pillar 3- 
Enhanced office systems to facilitate immunization; and Pillar 4- Motivation through 
immunization champions (Nowalk, et al., 2016). This program was being considered for 
commercialization at the time of this project and so permission was requested and granted to use 
the concepts from the program (Appendix C ). 
Kotter’s Eight Stages of Change Management 
Following Kotter’s (Kotter,1995) eight steps for successful change management helped to 
guide the organization and clarify the communication plan for the project. John Kotter, a 
professor of leadership at Harvard University during the 1990’s, studied over 100 companies and 
their organizational change efforts. He determined more than half of all major organizational 
changes fail due to a lack of interest or too much energy spent on resisting the change (Kotter, 
International, 2012). According to Kotter, the key to facilitating change is identifying why the 
organization resists change and then determining what process to use to overcome the resistance. 
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He developed eight stages to facilitate the change process and help leaders to understand their role 
in driving change. These eight stages include: 
 1. Creating Urgency. The first step involves helping others to feel the determination to 
take action and is driven by a belief that there are great opportunities as well as great hazards in 
the world. Kotter stressed that to initiate change, it is important to create a sense of urgency in 
order to overcome complacency. The sense of urgency for the need to develop and implement a 
change in service delivery was based on the alarming trends of increased patients within the 
organization with chronic HCV and made a compelling case for the organization to assemble a 
team of leaders within the organization who could spread the model to multiple clinic sites. 
Within this study site, the urgency came with the increased numbers of patients with HCV 
infection seen in the MAT programs needing immunized. The problem of low rates of HAV and 
HBV vaccination in adults with CHC described in the literature needed to be addressed within the 
organization along with the knowledge that performance measures needed to be met for the care 
of patients infected with HCV. Data obtained from baseline reports were used to strengthen the 
sense of urgency for the change. Providers and staff within the practice were expected to be 
motivated to improve vaccination rates by knowing the percentage of adult patients with CHC 
within the practice who were not fully immunized. 
2. Forming a Coalition. The second step calls for putting together a group with position, 
power, credibility, expertise, and leadership skills to lead the change. This was created through 
buy-in of the administrative staff after the project manager presented the quality improvement 
project to them according to the organization’s policy for research evaluation. The change project 
was explained and presented as an educational offering to the support staff and the provider team 
during their regularly scheduled meetings. Nurse managers trained in motivational interviewing 
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were recruited as immunization champions from each of the 5 primary care sites within the 
organization due to their knowledge of vaccine administration and their ability to share current 
evidence- based immunization guidelines and recommendations. Enlisting the expertise of the 
nurse managers of the clinical sites facilitated learning and change.  They championed the cause 
of immunizing patients with CHC against HAV and HBV and organized pre-visit planning 
activities to help avoid missed opportunities for vaccinating patients.  
3. Creating a Vision. A clear vision is developed to guide the change is the third step. The 
project facility has a mission statement, “To improve the lives of people in the communities we 
serve by treating their illness and helping them stay healthy”. This quality improvement project 
helped improve the lives of adult patients with CHC within the organization by providing 
preventive treatment with HAV and HBV vaccinations to protect the health of their livers.  
4. Communicating the Vision. Using strategies from the 4 Pillars™ Practice 
Transformation Program for the change project enabled the project manager to communicate the 
vision using a clear, simple model. The staff and providers were advised of the important role 
they play in the success of the project. There was an open line of communication with the project 
manager and the staff was encouraged to ask questions at any point in the intervention. An in-
house educational presentation created by the project manager included a review of the current 
recommendations for immunizing patients with CHC against HAV and HBV, interpretation of 
laboratory results for HAV, HBV, and HCV, vaccine schedule for HAV and HBV, vaccine 
administration guidelines, and frequently asked immunization questions. The project manager 
was able to communicate the vision of this new model and encourage providers and staff to act by 
presenting educational materials and strategies to support immunization of adult HCV infected 
patients at the FQHC clinic sites. Reporting the organization’s status on meeting performance 
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measures were clearly communicated through email communication with the facility staff and 
verbally at staff, administration, and board meetings. 
5. Short-Term Wins. The immediate improvement in the overall vaccination rate of the 
patient population was a short- term win for the FQHC. Small successes were celebrated each 
week during morning huddle meetings of the support staff, and the staff felt rewarded for their 
efforts when a patient with HCV infection had initiated the series of vaccinations and lessened the 
risk of developing the serious life- threatening complications of cirrhosis or HCC. A gourmet 
cupcake celebration occurred halfway through the project to keep motivation high and providers 
and staff focused on completion of the project.  
6. Removing Obstacles. According to Kotter (Harvard Business Review, 2012), ensuring 
that the organization removes barriers will accelerate movement toward the vision and the 
opportunity. Encouraging staff to use the standing orders that are in place for immunizations  
expedited the process of preventive care and decreased missed opportunities. Standing orders 
have been shown to significantly improve adult vaccination by eliminating barriers such as the 
time required for the provider to assess vaccination status and issue a verbal or written order to 
vaccinate (Yonas, Nowalk, Zimmerman, Ahmed, & Albert, 2012). Having immunization 
champions to maintain sufficient vaccine stock within the clinic sites was an important part of 
avoiding missed opportunities for vaccinating patients. Open-access, walk-in appointments for 
immunizations were also good strategies to facilitate completion of vaccine series. 
7. Continuing Change. In step seven of Kotter’s eight stages of change, the leader builds 
on successes and identifies areas to improve. During the project intervention, the immunization 
champions and project manager highlighted progress in increasing HAV and HBV vaccinations at 
morning huddle meetings and on charts placed on the refrigerators where the vaccines were 
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stored. Data was shared at the organization’s monthly quality improvement meetings. At the end 
of the intervention period, results and final statistical analysis was shared with the organizations’ 
leadership, quality improvement committee, staff, and the board of directors. Input was requested 
from the staff regarding program weaknesses and areas that can be built upon for continued 
development and improvement of the process of care for adult patients with HCV at the FQHC.  
8. Maintaining the Change. In the last step of Kotter’s change model, the change is 
solidified into the organizational culture. At the completion of the project, after review of the 
change process, the organizational leadership examined ways to incorporate improvement of 
vaccination rates as part of practice standards of care for adult patients with HCV, with a plan for 
succession. With the high number of HCV-infected patients seen in the FQHC, HCV protocols 
will be updated using EMR decision support to increase testing for HVC. Anti-HCV testing will 
be added to routine lab testing, such as cholesterol screening to help identify seropositive baby 
boomer patients. The project manager, an HCV champion, must continue to address barriers to 
implement EMR prompts for HCV testing, including system barriers: inability to make any IT 
programming demands due to large proprietary EMR limitations; clinician barriers: “Prompt 
burn-out”; and patient barriers: lack of insurance coverage for testing.   Quality measurement in 
HCV care has the potential to affect clinical practice, and maintain the improved rates of 
immunizations, especially when quality measures for immunizations will eventually affect 
reimbursement rates for the FQHC (Kanawal, 2012). 
Project Design 
Evidenced Based Project Intervention Plan 
The primary intervention employed to change current practice and improve HAV and 
HBV vaccination rates in adult patients with HCV at the sites used evidence-based strategies from 
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the 4 Pillars™ Practice Transformation Program (Appendix C). Strategies included: open-access 
nurse visits, using all visits to vaccinate, standing orders, posters, patientreminder postcards 
(Appendix D), use of EMR patient alerts, immunization champions, progress charts and 
staff/provider education (see Figure 1). 
 
Figure 1. Project model. Adapted from the University of Pittsburgh’s 4 Pillars™ Practice 
Transformation Program.  Retrieved from http://www.4pillarstoolkit.pitt.edu/ and Kotter 
International. (2012). The 8-step process for leading change. Retrieved from  
http://www.kotterinternational.com/our-principals/changesteps 
 
The primary goal of this project was to determine the effectiveness of an intervention to 
increase hepatitis A and B vaccination in adults with HCV that included using strategies from the 
4 Pillars™ Program, and staff/provider education. Based upon published clinical guidelines and 
performance measures for optimal care of HCV-infected persons, a quality improvement project 
was implemented guided by Kotter’s eight-step change model.  Strategies adopted from the 4 
Pillars™ Practice Transformation Program, including staff/provider education, vaccination, EMR 
reminders, patient post card reminders, and weekly charts to track progress standing orders, 
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immunization champions, open access/walk-in vaccination during office hours, posters promoting 
were used. Retrospective EMR reviews from CHC patients with detectable HCV RNA were 
conducted at the start of the project and three months following the intervention. Demographic 
data along with HCV viral load (HCV RNA), HAV total antibody (HAV Ab), HBV surface 
antibody (HBsAb), and vaccination against HAV and HBV were derived from EMR reports, 
comparing vaccination rates before and after the intervention. Secondary goals included 
increasing provider/staff knowledge related to CHC infection and clinical guideline 
recommendations for immunization against HAV and HBV. 
 Guidelines and Benchmarks for CHC Care 
Strong evidence supports HAV and HBV vaccination in patients with chronic liver 
disease, and is endorsed by the clinical  guidelines set forth by the American Association for the 
Study of Liver Diseases and the Infectious Diseases  Society (AASLD-IDSA, 20017) in addition 
to:  the ACIP,  the World Health Organization, the National Institute of Health, the American 
Liver Foundation, the American College of Gastroenterology, and the Department of Veterans 
Affairs Hepatitis C Resource Center Program (Fiore, Wasley, & Bell, 2006; Yee, Currie, 
Darling,& Wright, 2006).The Centers for Medicare and Medicaid Services adopted vaccination 
against HAV and HBV in patients with CHC infection as a quality measure in 2008 (Waghray, et. 
al., 2016).  In 2012, the CDC expanded its guidelines originally issued in 1998 for risk-based 
HCV testing with a recommendation to offer a one-time HCV test to all persons born from 1945 
through 1965, without prior ascertainment of HCV risk factors (AASLD-IDSA). Healthy People 
2020 includes objectives to increase HBV vaccine coverage among high-risk populations, 
increase HBV vaccine coverage among injection drug users, increase the proportion of persons 
who have been tested for HBV within minority communities experiencing health disparities, and 
HEPATITIS VACCINATION IN ADULTS WITH HEPATITIS C 31 
 
 
increase the proportion of persons aware they have a HCV infection (Healthy People,2020).The 
proposed 2020 goals of the US National Viral Hepatitis Action Plan for 2017-2020 has four goals: 
increasing from 33% to 66% the persons who are aware of their HBV infection, increasing from 
45%  to 66% the proportionof persons who are aware of their HCV infection, reducing by 25% 
the number of new HCV infections, and eliminating mother-to-child HBV transmission (US  
DHHS, 2017). To achieve these goals, the plan specifically targets education of providers and 
communities. It is unclear to what extent patients with HCV meet these recommendations. 
Overall, vaccination for viral hepatitis has been reported to be poor with less than 60% of patients 
with HCV meeting quality measures for vaccination (Kramer, Hachem, Kanwal, Mei, & El-Serag, 
2011). With the advent of these proposed goals, the importance ofunderstanding the current 
processes of care for HCV-infected patients and assessing quality gaps for immunization is 
warranted.  
Congruence of Organization’s Strategic Plan to Project 
This project supports the mission, values, goals and strategic plan of FamilyCare Health 
Centers. The mission of FamilyCare is “to improve the lives of people in the communities we 
serve by treating their illness and helping them stay healthy”. The intervention aimed to improve 
the health status of adult patients with CHC through vaccination against HAV and HBV. Hepatitis 
C services were identified as a strategic priority by FamilyCare’s administration and Board of 
Directors in 2014.With the basic infrastructure for this project currently in place, this project fit 
entirely within the framework FamilyCare has created through their Behavioral Health Integration 
funding. (See Appendix K Letter of Support). 
The clinical change project was constructed as a quasi-experimental, one group pre-
test/post-test design, with a convenience sample of family medicine providers and staff members  
HEPATITIS VACCINATION IN ADULTS WITH HEPATITIS C 32 
 
 
from five primary care sites within a large FQHC in West Virginia who were attending their 
monthly staff meeting on January 3, 2018. During the provider/staff education phase, an 
evidence-based educational curriculum on The Role of Vaccinating Adult Patients with HCV 
against HAV and HBV in the Prevention of Cirrhosis and HCC was developed by the project 
manager according to evidence-based recommendations from the CDC, to assist providers and 
staff members in ordering appropriate laboratory testing, interpreting laboratory test results, and 
ordering hepatitis vaccinations for adults with HCV. Strategies from the 4 Pillars™ Practice 
Transformation Program were presented (Appendix E). The pretest-posttest was developed based 
on the review of the literature and evidence-based quidelines.  
 Procedure 
Following the IRB review and approval in Decmeber 2017, the educational program was 
presented in a power point session at a monthly family medicine provider/staff member meeting 
to physicians, nurse practitioners, physician assistants, and staff members on January 3, 2018. 
(Appendix E).   Use of educational posters placed in each of the break rooms at five clinic 
locations, provided easy access to providers and staff, and was an efficient way for the 
immunization champions to present the strategies (Appendix F). 
 Data on effectiveness of education for the diagnosis of HCV and the role of HAV and 
HBV vaccination in preventing cirrhosis and HCC was evaluated using a pre/posttest 
questionnaire, “Hepatitis Knowledge Assessment” (Appendix G).  
Patients ages 18 years and older with a detectable HCV RNA, defined as a measurable 
quantifiable viral load were included in the retrospective chart review. Because immunization is a 
dynamic, measurable area of healthcare and the patient population was already involved in the 
immunization process, the abbreviated timeframe of three months was used for the 
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implementation and evaluation of the project, looking at vaccination rates at two points in time: at 
the start of the project before the educational intervention, and at the end of the three-month 
project. The accessible population of persons in the FamilyCare Hepatitis C EMR report included 
a total of 278 patients. All patients who were anti-HCV-positive only but did not have HCV RNA 
testing or a negative HCV RNA result were excluded which resulted in a sample of 130 patients 
from the pre-intervention data and 229 patients from the post-intervention data. The FQHC used 
an EMR system that included clinic visit notes, diagnostic codes of the clinic encounter, all 
prescriptions, andlaboratory data in searchable form. Descriptive statistics were used to describe  
baseline vaccination rates for HAV, HBV, and HAV/HBV, with the goal of a 20% increase in the 
post-intervention data gathered.  Demographic data such as age, gender, and insurance were 
reported.  HCV viral load (HCV RNA), HAV (HAVab), HBV surface antibody (HBsAb), and 
vaccination against HAV and HBV were derived from EMR reports, comparing vaccination rates 
before and after the quality improvement project with the assistance of the IT staff at FamilyCare. 
All personal health information was de-identified before data analysis was completed. 
Nurse managers in each of the five family medicine sites were recruited as immunization 
champions. Health coaches were an initial consideration for serving as immunization champions, 
however, there were not health coaches at each of the sites. The nurse managers were chosen as 
they are most often responsible for ordering immunizations and are the lead clinicians for 
educating the support staff.  The immunization champions placed awareness posters in each of the 
examination rooms, (Appendix H) and posted weekly progress charts on each of the clinic 
refrigerators where vaccines were stored (Appendix I). Immunization champions kept track of 
vaccine stock and made sure there were vaccines available in the clinics in order to avoid missed 
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opportunities. They reported progress in Monday morning huddle meetings, and led the staff in 
pre-visit planning activities, another strategy that may help to avoid missed opportunities.   
Timeline of Project Phases 
As depicted in Figure 2., Project Timeline, the entire project from selecting a capstone 
committee in March of 2017, to IRB submission, and then to completion spanned over 12 months. 
Dates in the projected timeline were adjusted as needed based on unforeseen circumstances that 
might have occurred for the project manager. In this project, the timeline for beginning the project 
had to be delayed until the beginning of 2018, as the IRB approval was not received until 
December. Because staff meetings are only held once a month, it was imperative that the project 
began at the beginning of January at the first monthly staff meeting of the year in order to gather 
three months of data. The timeline for the project was divided into three phases: Phase 1-Summer 
Semester 2017, Phase 2-Fall Semester 2017, and Phase 3-Spring Semester 2018. The 
development phase of the intervention began with completion of a draft of the proposal paper at 
the end Summer Semester 2017.  The development phase was completed after final revisions 
from the full capstone committee were reviewed and all materials to be used for the project were 
finalized. The project was approved by the Institutional Review Board of West Virginia 
University on December 19, 2017 during Phase 2-Fall Semester. Project implementation began in 
January at the beginning of Spring Semester 2018. The project was implemented during the 
months of January, February, and March with data analysis and write up occurring at the end of 
March of 2018. A formal oral defense presentation of the results was on April 2, 2018 prior to 
graduation in May of 2018 (See Figure 2). 
 




Figure 2.  
Resources:  Personnel, Technology, and Budget 
The cost of the project was difficult to actually determine, as the largest cost was the 
salaries/wages of the staff and providers. FamilyCare was responsible for the respective 
employees’salaries, and thus they participated in the intervention at no cost to the project 
manager.Additional costs to the organization were minimal. The staff was already in place and 
working in the five primary care sites where the project took place, providing reimbursable care 
for the clinic visits. There may be some additional payer reimbursement for immunizations 
provided to patients with private insurance. However, most of the HCV patient population is 
covered by Medicaid and the cost for the vaccines was wrapped into a set fee for each visit. 
Although it is not likely there would be a significant return on investment for the health center in 
terms of revenue generated, completing the series of vaccinations requires returning to the clinic 
for follow up after initial testing to determine immune status.  This involves additional visits 
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which could provide some additional income for the organization. There was no cost to the 
project director for classroom space, and audiovisual equipment. Another cost was the time the 
project director spent gathering pre- and post-data, implementing the intervention, and 
disseminating the data collected, which will be free.  
There were projected to be 10 physicians, 11 advanced practice clinicians, 6 registered 
nurses, 5 LPNs, and 30 medical assistants participating in the project. The investigator estimated 
the cost of nursing salaries to be $420.00 dollars by taking an average of $20.00 dollars per hour 
for registered nurses, $12.00 dollars per hour for the LPNs, and $8.00 dollars per hour for the 
medical assistants. Cost for the participation of the advanced practice clinicians was estimated at 
$495.00 dollars by allowing $45.00 dollars per hour. Physician salaries were estimated to be 
$1,250.00 dollars by allowing $125.00 dollars per hour. In order to provide an educational 
intervention lasting approximately one hour at the beginning of the project and manage the 
quality improvement project over the course of the project, the nurse practitioner investigator will 
be needed for five hours per week for 12 weeks at a cost of $2,700.00 dollars. The total cost for 
time to participate was projected to be $4,829.00 dollars (Appendix J). 
The investigator estimated the cost of the operating budget to be as follows: posters for 
exam rooms $100.00 dollars, patient reminder cards $250.00 dollars, badges for immunization 
champions $50.00 dollars, posters for nursing staff break rooms $ 125.00 dollars, hospitality 
$200.00 dollars. The total cost of the operating budget was projected to cost $725.00 dollars. The 
overall total cost of the intervention was projected to cost $5,554.00 dollars. (Appendix M). 
Long-term healthcare cost savings will be generated by reducing morbidity and mortality 
associated with the high burden of disease from CHC expected over the next 10-15 years, 
including the life-threatening hepatic complications of cirrhosis and HCC. With a growing need 
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for advanced practice registered nurses to serve patients in rural and underserved areas, the 
project, “Improving Nursing Scholarship, Practice, Innovation, Research, and Education to Care 
for WV (INSPIRE to Care for WV)” was implemented by a team of faculty from the West 
Virginia School of Nursing through a three-year, $1.2 million grant from the Health Resources 
and Services Administration. Grant funds were anticipated from the INSPIRE project at West  
Virginia University to help cover the cost of the project but were not needed to complete the 
project.  
Measurable Project Objectives 
 Specific outcomes to be achieved/evaluated as part of this capstone were:   
1. Provider/staff knowledge regarding hepatitis A and B immunizations for adult    
patients with HCV diagnosis would improve after one educational session as  
evidenced by a change from pretest to posttest knowledge score. 
 2. By the end of the project, immunization rates for HAV (Havrix), HBV  
(Engerix-B), and HAV/HBV (Twinrix) would improve following the quality  
improvement project as evidenced by a 20% overall increase in rates using  




 To meet objective 1, the health care providers’ and staff members’ knowledge 
related to CHC infection and clinical guideline recommendations for immunization against HAV 
and HBV were evaluated before and after an educational presentation using 20 items from a 
pretest-posttest questionnaire (Appendix I). The pretest, educational presentation, and post-test 
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was administered to providers by the project manager at their monthly staff meeting, and the 
pretest, educational presentation, and posttest was administered to the staff members at their 
monthly staff meetings by nurse managers at each of the sites. A change in knowledge from pre-
test to post-test was measured with a paired t- test. 
To evaluate objective 2, descriptive statistics were used to describe baseline vaccination 
rates for HAV, HBV, and HAV/HBV, with the goal of a 20% increase from baseline. De-
identified retrospective EMR reports from CHC patients with detectable HCV RNA were 
conducted at two time points: prior to and threemonths following the provider/staff education 
intervention. Demographic data along with HCV viral load (HCV RNA), HAV total antibody 
(HAV Ab), HBV surface antibody (HBsAb), and vaccination against HAV, HBV, and 
HAV/HBV were derived from the de-identified EMR reports, comparing vaccination rates prior 
to the implementation and three months after the implementation. Because HAV (Havrix) is given 
as a 2-dose series, at 0 and 6 months, and HBV (Engerix B ) and HAV/HBV (Twinrix) are given 
as a 3-dose series at 0, 1 and 6 months, the primary outcome measures were the percentage of 
patients who were eligible to receive HAV and HBV vaccination  (+HCV RNA)  and actually 




Provider/Staff and Patient Demographics 
 A total of 50 people, 14 providers, mostly physicians and nurse practitioners and 36 staff 
members, mostly medical assistants attended the one-hour, educational session (see Table 1.) 
 






     Providers 
     Freq (%) 
Characteristic    N=50________________________________________ 
Clinical Title 
Nurse Practitioner   4 
Physician    9 
Physician’s Assistant   1 
RN     2 
LPN     14 
Medical Assistant   20 
________________________________________ 
 
Years in Practice 
Nurse Practitioner   2-17 yrs. 
Physician    5-25 yrs. 
Physician’s Assistant   8yrs. 
RN     2-23 yrs. 
LPN     1-22 yrs. 

















The educational intervention significantly increased the providers’ and staffs’ knowledge 
about hepatitis C. There was an average gain of 16.76 points (95% confidence interval, 13.32, 
20.20) on a knowledge test after the educational presentation. This gain was statistically 
significant at p ≤ .05 by the paired t-Test (see table 2) 
Table 2 
Paired Samples Test 
 
 


















16.80000 12.36189 1.74824 13.28679 20.31321 9.610 49 .000 
 
 
 There was concern for validity of results as there was a low degree of implementation 
fidelity. One nurse manager allowed the participants in her group to have access to the  
educational presentation during the posttest which may have increased their scores. Several 
participants did not put their names on the questionnaires and so these could not be included in 
the evaluation. A typographical error was discovered when the project manager was scoring the 
pretests and posttests which required discarding several questions and re-numbering the 
remaining questions in order to have the same 20 questions on each of the tests.   
Patient Demographics 
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 The pre-intervention sample included 130 patients. Ages ranged from 19 to 75 with the 
mean age 41.03 (see Table 3).  The mean age for the post-intervention sample was 40.30. Women 
accounted for 55.4% of the population in the pre-intervention group and 53.7% in the post-
intervention group which is consistent with the general patient population at FamilyCare where 
61.1% are women (UDS reporting, 2017). The FQHC recently began providing urgent care and 
chronic care services to a local long-term addiction treatment center for women which could also 
have increased the number of women patients in the sample.   The majority of patients were 
insured by Medicaid (79.2%). Medicare accounted for 19.2% of patients’ health insurance. There 
were 2 patients who were uninsured (1.5%). Although FamilyCare does see patients with 






 N Minimum Maximum Mean Std. Deviation 
age 130 19.00 75.00 41.0308 12.98296 







 N Minimum Maximum Mean Std. Deviation 
age 229 20..00 75.00 40.3013 12.54574 
















Valid Male 58 44.6 44.6 44.6 
Female 72 55.4 55.4 100.0 




 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid male 106 46.3 46.3 46.3 
female 123 53.7 53.7 100.0 






 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Medicaid 103 79.2 79.2 79.2 
Medicare 25 19.2 19.2 98.5 
Other 2 1.5 1.5 100.0 















 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Medicaid 173 75.5 75.5 75.5 
Medicare 32 14.0 14.0 89.5 
Other 24 10.5 10.5 100.0 





Pre-intervention baseline rates of Havrix, Engerix-B, and Twinrix vaccinations were 
established from the retrospective review of 130 patients with HCV (see Table 6). Post-
intervention rates of these vaccinations were collected from retrospective chart reviews of 229     
patients with HCV at the end of the three- month quality improvement project to evaluate the 
percentage of patients with HCV who had vaccinations. Due to prior immunity from previous 
exposure to HBV or vaccination outside of the clinic, only 2.3% of patients met the performance 
measure for HBV vaccination in the pre-intervention group.  Improvements were seen for Havrix 
(16.9% pre-intervention, 19.7% post-intervention); Engerix-B (2.3% pre-intervention, 3.5% post-
intervention); and Twinrix (20.8% pre-intervention, 21.4% post-intervention).  Compared with 
the baseline sample (n=130), there was an overall 4.6% increase in vaccination rates in the post-
intervention group. The project manager found overall adherence to the performance measure to 
vaccinate all HCV-positive patients for HAV and HBV was 40.0% in the pre-intervention group 
and 44.6% in the post-intervention group. This is considerably lower than a previous Veterans 
Administration study that demonstrated combined rates for HAV and HBV at 62% (Thudi, et al.,  
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 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Havrix 22 16.9 16.9 16.9 
Engerix B 3 2.3 2.3 19.2 
Twinrix 27 20.8 20.8 40.0 
No vaccine 78 60.0 60.0 100.0 






 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Havrix 45 19.7 19.7 19.7 
Engerix-B 8 3.5 3.5 23.1 
Twinrix 49 21.4 21.4 44.5 
no vaccine 127 55.5 55.5 100.0 
Total 229 100.0 100.0  
 
Program Cost and Sustainability 
The project came in under budget as outlined in Appendix M ($ 1,084.88 vs. $5,480.00) 
with the additional cost for postage that was not included in the projected budget. Two of the 
strategies from the 4 Pillars™ Practice Transformation Program were already in use at the sites, 
including walk-in immunizations and standing orders which allow non-physician personnel to 
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assess patients’ immunization status and administer vaccines without an individual physician 
order.  Standing order programs are a proven method of increasing adult immunizations (Nowalk, 
et al., 2014), and hopefully will be utilized more often since the educational intervention, which 
was intended to enhance staff effectiveness with managing hepatitis immunizations for adult 
patients with HCV.  The patient alert in the EMR is an existing tool as well that can be employed 
specifically for alerting staff/providers when the next immunization is due and the patient’s 
immune status. 
Discussion and Recommendations 
Successful implementation of this change project improved quality of care by expediting 
the application of an evidence-based model to improve HAV and HBV vaccination rates in adult 
patients with CH across five FamilyCare sites. The project increased awareness of hepatitis C as a 
serious health problem.  There was an increase in the number of patients who asked about being 
tested for hepatitis. With increased knowledge, providers and staff encouraged patients to get 
tested which is evidenced by the increased number of patients in the post-intervention sample. 
This project had several limitations. One of the limitations is that the project was conducted 
within a single FQHC system, which serves a majority of patients that are publicly insured and 
therefore may limit the generalizability of the results. Other weaknesses included reliance on a 
retrospective manual chart review for data collection. The small sample size with no long-term 
follow-up did not allow for observation of completion of the vaccine series.   
These findings suggest that healthcare providers do not frequently identify candidates for 
HAV and HBV vaccination as part of routine clinical services, even though HAV and HBV 
vaccination is recommended for persons with CHC. Continued focus on increasing provider/staff 
knowledge related to hepatitis A, B and C virus is recommended to ensure the vaccination rates 
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will improve as lack of adequate counseling and patient education may be a factor in patient 
compliance with vaccine recommendations. More emphasis needs to be placed on routine viral 
hepatitis screening, vaccination, and follow up for post-vaccination testing to check for immune 
status. Gaps in the literature show that future studies on interventions to increase immunization 
rates should include adequate follow up time to capture completion of the vaccination series and 
testing for immunity following vaccination, which supports the findings from this study. In 
addition, studies that examine the determinants for non-adherence for both patients and providers 
will be valuable information to help increase hepatitis immunization rates in persons with chronic 
hepatitis C, in any healthcare setting. 
Conclusion 
 Rapid development of new HCV treatments along with increasing numbers of people being 
identified with HCV has increased the need for updated expert clinical guidance. The DNP will 
play a critical role in building health care provider capacity to diagnose and treat HCV. Accurate 
testing to identify current infection is important to help clinicians and other providers correctly 
identify patients with HCV so that preventive services can be offered. The ability of patients to 
improve their health is directly related to the quality of the prevention and care services offered 
(Quaglio et al.,2006). Notifying tested persons of their infection status, enabling them to make 
informed decisions about medical care and options for treatment, along with taking measures to 
limit HCV-associated disease progression by vaccination against HAV and HBV is paramount to 
improving the health of adult patients with HCV. Multi-strategy, evidence-based interventions were 
an effective means of increasing hepatitis A and B vaccinations in a community health center and 
led to increased access to vaccination services, increased community demand for vaccines, and 
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improved system-based performance.  However, vaccination rates were only increased by 4.6% in 
a predominantly publicly insured patient population. 
Attainment of DNP Essentials 
  Nursesplay a significant role in preventing viral hepatitis. As educators, nurses teach  
healthcare providers and communities to reduce health disparities. Leveraging the expertise of 
advanced practice nurses’ ability to provide accurate education and information regarding 
screening, testing, surveillance, and evaluation of the impact of strategies to immunize and 
prevent new hepatitis infections is integral to achieving the current goals for the care of patients 
with viral hepatitis.  Completing this quality improvement project has given the project manager 
the experience needed to fulfill the Essentials of Doctoral Education for Advanced Nursing 
Practice. The DNP candidate utilized Kotter’s evidence-based change model as a theoretical 
framework. Borrowing strategies used in the 4 Pillars Practice Transformation program helped 
her to lead a primary care team in increasing hepatitis A and B vaccinations in adults with HCV 
in a community health center across 5 sites based on a foundation in clinical prevention and 
population health. The project manager gained clinical expertise in current hepatitis A and B 
vaccination recommendations that improved patient outcomes. The project manager was able to 
demonstrate advanced nursing practice and specialization by developing and implementing an 
educational presentation for primary care providers and staff and applying clinical scholarship 
and analytical methods to design and direct quality improvement. Information systems technology 
was utilized to manage population level data and disseminate new information to the organization 
on the quality of care provided to patients with hepatitis C. 
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Definition of Terms 
  
CDC: Centers for Disease Control and Prevention          
CHC: Chronic Hepatitis C      
DNP:  Doctor of Nursing Practice 
EMR:  Electronic medical record 
FQHC:  Federally Qualified Health Center 
HAV: Hepatitis A Virus  
HBV: Hepatitis B Virus 
HAVab:  Hepatitis A antibody 
HBcAb:  Hepatitis B Core Antibody 
HBsAb: Hepatitis B Surface Antibody     
HCC:  Hepatocellular cancer 



























Thank you for coming in to FamilyCare today for your ____________________________. 
 
Your next immunization is due on:___________________. 
 
You may walk-in without an appointment between 830 AM and 400 PM for a nurse to give 
you your injection. Please call us at ______________if you are unable to come in on this 
date so we can advise you of another date. It is important to complete your immunization 













From: Virginia Selanik [mailto:virginia.selanik@familycarewv.org]  
Sent: Thursday, June 08, 2017 1:23 PM 
To: Weber, Carolyn J <cweber@innovation.pitt.edu> 




I respectfully request your permission to use the 4 Pillars™ Practice 
Transformation Program developed at the University of Pittsburgh as an intervention model for my 
doctoral project. 
  
I am requesting permission to use the 4 Pillars Transformation Program concepts to guide my DNP 
capstone project, a quality improvement evaluation on increasing Hep A and B vaccination rates in 
adult patients with HCV in a Federally Qualified Health Center. I would not be using the step-by-step 
registered program, just the concepts and some of the intervention strategies, so I am not sure if  I am 
understanding the terms of usage.  It is my intention to publish the results of the project and if you 
grant permission for use, I will state that it is used with your permission. 
  
I sincerely appreciate your consideration of this matter. Please advise me of your decision and I will 
gratefully forward it to my committee chair, Emily Barnes, DNP, FNP-BC. 
  




Virginia M. Selanik, APRN, FNP-BC 





Virginia M Selanik, APRN, FNP-BC 
FamilyCare Health Centers 
116 Hills Plaza 
Charleston, WV 25387 



















From: Weber, Carolyn J  
Sent: Thursday, June 08, 2017 2:42 PM 
To: Virginia Selanik <virginia.selanik@familycarewv.org> 
Cc: Raviotta, Jonathan Marc <jraviotta@pitt.edu> 




Thank you for your interest in using the 4 Pillars™ Practice Transformation Program developed here at 
the University of Pittsburgh.  Currently, this program is being considered for commercialization and the 
step by step registration is not available.  You indicate that you would not be using this 
feature.  Perhaps if you need to track this, it will be available for research and/or educational purposes 
in the future. 
  
You are free to use any of the publically available information on the website to improve or increase 
vaccination rates.  You will need to cite the source of information in your publication. 
  
I am copying the lead innovator on this program to provide any additional information on the usage of 
the site at this time should you require it. 
  





Carolyn J. Weber, MBA 
Licensing Associate 
 
1st Floor Gardner Steel Conference Center (GSCC) 
130 Thackeray Avenue 
Pittsburgh, PA 15260 
  
(412) 383-7670- Innovation Institute 




























From: Raviotta, Jonathan Marc [mailto:jraviotta@pitt.edu]  
Sent: Thursday, June 08, 2017 3:30 PM 
To: Weber, Carolyn J; Virginia Selanik 
Cc: Zimmerman, Richard (zimmrk@UPMC.EDU) 
Subject: RE: Terms of Usage for the 4 Pillars Practice Transformation Program 
  
Virginia, 
We appreciate your interest in the 4 Pillars content as well as your commitment to immunization. As 
Carolyn mentioned, we are hoping to bring the program to a national audience in a sustainable way so 
some of the interactivity of the program is invisible to anonymous users. We do hope that you find the 
public information helpful and would welcome any feedback or suggestions as you work to implement 
change in your practice. 
  
I have attached our project snapshot which has a list of publications about the program. You may find 












The Role of Vaccinating Adults with HCV Against HAV and HBV in the Prevention of 
Cirrhosis and Hepatocellular Carcinoma 
 
1. Introduction 
    a.  Purpose of presentation 
    b.  Personal interest in care of patients with HCV in primary care 
    c.  How project came about 
    d.  Background and significance of problem 
    e.  Problem Statement:   
 
2. Acute HAV or HBV with HCV associated with increased morbidity and mortality 
    a. The role of vaccination 
    b. Literature Review  
3. Testing and Interpretation of Laboratory Results for Hepatitis A, B, and C  
     a. Recommendations          
4.  Practice Change Project 
     a. Using multiple strategies from the 4 Pillars™ Model 
  





















































































 Appendix G 
 
Pre-Test for Providers/Staff 
 
“A Hepatitis Knowledge Assessment” 
 
 
1-  The most effective way to prevent hepatocellular cancer due to chronic hepatitis B and 
chronic      
      hepatitis C is to prevent viral hepatitis through immunization. 
 




 2-   Currently there is an effective vaccine against hepatitis C virus. 
 
  TRUE          FALSE 
 
3-   Hepatitis C accounts for most of the hepatocellular cancer in the US. 
 
  TRUE         FALSE 
 
4-     Hepatitis A and Hepatitis B vaccination is less effective in patients with advanced liver  
        disease. 
 
  TRUE         FALSE 
 
5-     Chronic hepatitis B and chronic hepatitis C co-infection are associated with: 
a.  More severe laboratory abnormalities 
  b.  Worse histologic disease 
  c.  Higher fatality rates 
  d.  More complications of cirrhosis 
  e.  Higher incidence of hepatocellular cancer 
  f.   All of the above 
 
    Hepatitis A appears only as an acute or “newly occurring” infection and does not become 
          Chronic. Persons affected with Hepatitis A usually improve without treatment. 
(Question not counted)) 
 
  TRUE          FALSE 
 
(6) 7-       How prevalent is hepatitis C in the US? 
  a.   2.7-3.9 million people are infected 
  b.   1.5-2.0 million people are infected 
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c.   Hepatitis C Affects approximately 2% of the US population 
  d.   a. and c. 
  e.   b. and c. 
 
(7))8-        Hepatitis C is treatable and can be cured. 
   
  TRUE          FALSE 
 
(8)9-        Hepatitis C virus can survive outside the body at room temperature for three 
weeks. 
TRUE          FALSE 
 
(9)10-      Who is at risk for hepatitis C infection? 
 
  a.  Past injection drug users who only used 1x many years ago 
  b.  People who received a blood product for clotting problems made before 
1987 
  c.  Recipients of donated blood or solid organ transplants before 1992 
  d.  a. and c. 
  e.  All of the above 
 
10)11-      What is the risk of a pregnant woman passing hepatitis to her baby? 
 
  a.  Hepatitis is rarely passed from a pregnant woman to her baby 
  b.  About 6 of every 100 infants born to mothers with hepatitis C 
  c.  Risk is increased if mother is co-infected with HIV 
  d.  b. 
  e.  All of the above 
 
 -       Of every 100 people infected with hepatitis C, about: 
 
  (11)a.  75-85 people will develop chronic hepatitis C infection, and of those: 
 















(12)b.  60-70 will go on to develop chronic liver disease  
 
  TRUE           FALSE 
 
  (13). 5-20 will develop cirrhosis over a period of 20-30 years 
   
  TRUE          FALSE 
 
  (14)d.  1-5 will die 
  
TRUE           FALSE 
 
  In WV, between 2011 and 2015: 
 
  (15)a.  Reported rates of acute hepatitis A did not increase 
 
  TRUE          FALSE 
 
  (16)b.  Reported rates of acute hepatitis B increased by 146% 
 
  TRUE          FALSE 
 
  (17)c.  Reported rates of acute hepatitis C increased by 36% 
   
  TRUE          FALSE 
 
(18) 15-       What blood tests are used to detect hepatitis C infection? 
   
  a.  Screening tests for antibody to HCV (anti-HCV) 
  b. Qualitative tests to detect presence or absence of virus (HCV RNA by 
PCR) 
  c. Quantitative tests to detect amount (titer) of virus (HCV RNA by PCR) 
  d.  All of the above 
 
(19)16-        How soon after exposure to HCV can HCV RNA be detected by PCR? 
                        a.  2-3 weeks after infection 
  b.  4-6 weeks after infection 
  c.  12 weeks after infection 
  d.  None of the above 
 
(20)17-         A patient can have a normal liver enzyme (e.g., ALT) and still have chronic    
                     hepatitis C. 
 
  TRUE          FALSE 






-         HCV-infected persons should be restricted from working in certain occupations or     
    settings. 
 
  TRUE          FALSE 
 
-         Women with HCV infection should be advised against breastfeeding if their nipples 
are  
    cracked or bleeding.(Question not counted) 
 




      How is hepatitis B transmitted?(Question not counted) 
 
  a. Unprotected sexual contact 
  b. Sharing drugs, needles, or “works” when using drugs 
  c.  Poor infection control practices with equipment to test blood glucose 
  d.  Needle sticks or sharps expose on the job 
  e.  From mother to baby during birth 
  f.  Contact with wound or skin sores 
  g.  When an infected person bites another person 
  h.  Pre-chewing food for babies 
   i.  Sharing personal care items, such as clippers, razors, or toothbrushes 
   j.  All of the above 

























Post-Test for Providers/Staff 
 




Age __________      Gender ____________       _Total years practicing as: 
        MD/DO: __________ 
        PA: ______________ 
        NP: ______________ 
        RN: ______________ 
        LPN: _____________ 
        MA: ______________ 
 
 
1-  The most effective way to prevent hepatocellular cancer due to chronic hepatitis B and 
chronic   
      hepatitis C is to prevent viral hepatitis through immunization. 
 
 
   TRUE       FALSE 
 
2-   Currently there is an effective vaccine against hepatitis C virus. 
 
  TRUE        FALSE 
 
3-   Hepatitis C accounts for most of the hepatocellular cancer in the US. 
 
  TRUE        FALSE 
 
4-   Hepatitis A and Hepatitis B vaccination is less effective in patients with advanced liver 
       Disease. 
 
  TRUE        FALSE 
 
5-   Chronic hepatitis B and chronic hepatitis C co-infection are associated with: 
 
  a.  More severe laboratory abnormalities 
  b.  Worse histologic disease 
  c.  Higher fatality rates 
  d.  More complications of cirrhosis 
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  e.  Higher incidence of hepatocellular cancer 
  f.  All of the above  
 
-   Hepatitis A appears only as an acute or “newly occurring” infection and does not 
become 
       Chronic.  
 
  TRUE        FALSE (question not counted) 
 
 
 -   Persons infected with hepatitis A usually improve without treatment. 
 
  TRUE        FALSE (question not counted) 
 
(6) 8-   How prevalent is hepatitis C in the US? 
 
  a.  2.7-3.9 million people are infected 
  b.  1.5-2.0 million people are infected 
  c.  Hepatitis C affects approximately 2% of the US population 
  d.  a. and c. 
  e.  b. and c. 
 
(7) 9-   Hepatitis C is treatable and can be cured. 
 
  TRUE        FALSE 
 
(8) 10-   Hepatitis C can survive outside the body at room temperature for three weeks. 
 
  TRUE        FALSE 
 
(9) 11-  Who is at risk for Hepatitis C infection? 
 
  a.  Past injection drug users who only used 1x many years ago 
  b.  People who received a blood product for clotting problems made before   
                             1987 
  c.  Recipients of donated blood or solid organ transplants before 1992 
  d.  b. 
  e.  All of the above 
 
(10) 12-  What is the risk of a pregnant woman passing hepatitis C to her baby? 
 
  a.  Hepatitis is rarely passed from a pregnant woman t her baby 
  b.  About 6 of every 100 infants born to mothers with hepatitis C 
  c.  Risk is increased if mother is co-infected with HIV 
  d.  b. 
  e.  All of the above 








13-  Of every 100 people infected with hepatitis C, about: 
 
  (11)a.  75-85 people will develop chronic hepatitis C infection, and of those: 
 
  TRUE        FALSE 
 
  (12) b.  60-70 will go on to develp chronic liver disease 
 
  TRUE        FALSE 
 
  (13) c.  5-20 will develop cirrhosis over a period of 20-30 years 
 
  TRUE        FALSE 
 
  (14) d.  1-5 will die 
 
  TRUE        FALSE 
 
14-  In WV, between 2011 and 2015: 
 
  (15)a.  Reported rates of acute hepatitis A did not increase 
 
  TRUE        FALSE 
 
   (16) b.  Reported rates of acute hepatitis B increased by 146% 
 
  TRUE        FALSE 
 
  (17) c.  Reported rates of acute hepatitis C increased by 36% 
 




(18)15-  What blood tests are used to detect hepatitis C infection? 
 
  a.  Screening tests for antibody to HCV (anti-HCV) 
  b.  Qualitative tests to detect presence or absence of virus (HCV RNA by 
PCR) 
  c.  Quantitative tests to detect amount (titre) of virus (HCV RNA by PCR) 
  d.  All of the above 









(19)16-  How soon after exposure to HCV can HCV RNA be detected by PCR? 
 
  a.  2-3 weeks after exposure 
  b.  4-6 weeks after exposure 
  c.  12 weeks after exposure 
  d.  None of the above 
 
 (20)17-  A patient can have a normal liver enzyme (e.gt. ALT) and still have chronic 
hepatitis C. 
 




-  HCV-infected persons should be restricted from working in certain occupations. 
(Question not counted) 
 
  TRUE        FALSE 
 
-  Women with HCV infection should be advised against breastfeeding if their nipples are  
        cracked or bleeding (Question not counted) 
 




-  How is hepatitis B transmitted? (Question not counted) 
 
  a.  Unprotected sexual contact 
  b.  Sharing drugs, needles, or works when using drugs 
  c.  Poor infection control practices with equipment to test blood glucose 
  d.  needle sticks or sharps exposure on the job 
  e.  From mother to baby during birth 
  f.  Contact with wound or skin sores 
  g.  When an infected person bites another person 
  h.  Pre-chewing food for babies 
  i.  Sharing personal care items, such as clippers, toothbrushes, or razors 
  j.  All of the above 
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                                                       Project Budget 
Operating Expenses Estimated Actual 
Nurse Salaries $           420.00  n/a 
Advanced Practice Clinicians 
Salaries 
$3,195.00 n/a 
Physician salaries $         1,250.00 n/a 
Posters in exam rooms $            100.00 $     300.00        
Posters in break rooms $125.00 $     288.00 
Patient reminder cards $250.00 $       85.00 
Badges for immunization 
champions 




Celebration at halfway mark 
$200.00 $   165.00 
Printing Services for consent 
forms, pre-post tests 
$250.00 $   244.88 
 $          5,480.00 $ 1082.88 
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